Samrat Pharmachem logo

Samrat Pharmachem financials and balance sheet

BSE: 530125Pharmaceuticals & BiotechnologySmall Cap

Last close ₹277.50down ₹10.60 (3.68%)

Share price at the BSE close on 23 Oct 2026. Previous close ₹288.10.

52-week range of traded prices to 23 Oct 2026
₹190.00Low, 30 Mar 2026₹309.85High, 30 Oct 2025
Market cap
₹86 Cr3,210th largest listed
P/E
Lossover the last 12 months
P/B
1.3
Dividend yield
Nonein the last 12 months
ROE
−3.2%
ROCE
−2.7%
Debt to equity
0.16
Volume, BSE
1,601

10 years at a glance

Standalone: the listed company alone, without its subsidiaries. ₹ crore, years to March.Samrat Pharmachem annual reports

Revenue, net profit and borrowings, ₹ crore

  • Revenue
  • Net profit
  • Borrowings
  • Loss
Peak revenue ₹311 Cr, year to Mar 2023A loss in the year to Mar 2026, −₹3.31 Cr

Operating and net margin, per cent

  • Operating margin
  • Net margin

Results for the year to Mar 2026

Standalone: the listed company alone, without its subsidiaries. ₹ crore.

From revenue to net profit

  1. Revenue290
  2. Materials and goods−283
  3. Employee costs−2.3
  4. Other expenses−6.5
  5. Operating profit−2.1
  6. Depreciation−0.7
  7. Other income+0.8
  8. One-off items0.0
  9. Finance costs−1.0
  10. Profit before tax−3.0
  11. Tax−0.3
  12. Net profit−3.3

What the company owns

  • Receivables₹51 Cr
  • Inventory₹44 Cr
  • Plant, investments and other assets₹23 Cr
  • Cash and bank₹6 Cr
  • Current investments₹0 Cr

What pays for it: net worth and liabilities

  • Net worth₹68 Cr
  • Owed to suppliers₹43 Cr
  • Borrowings₹11 Cr
  • Other liabilities₹3 Cr

Profit and loss

Standalone, ₹ crore, years to March.Samrat Pharmachem quarterly results

₹ croreMar 2017Mar 2018Mar 2019Filed 11 JunMar 2020Filed 6 AugMar 2021Filed 6 JulMar 2022Filed 10 JunMar 2023Filed 30 MayMar 2024Filed 4 JulMar 2025Filed 13 JunMar 2026Filed 30 May
Revenue from operations7193111137179222311282286290
6787108131170197287279276292
Materials and goods bought6382103126164190278270267283
Employee costs––11122222
Other expenses––44567777
Operating profit before depreciation463792424210−2
Operating margin5.3%6.4%2.9%4.8%4.8%11.0%7.7%0.9%3.6%−0.7%
Materials, % of revenue––92.3%91.4%91.7%85.6%89.4%96.0%93.3%97.7%
Employee costs, % of revenue––1.2%1.1%0.8%0.8%0.6%0.8%0.8%0.8%
Other expenses, % of revenue––3.6%2.7%2.6%2.6%2.2%2.3%2.3%2.3%
Depreciation and amortisation1000011111
Operating profit after depreciation363682423210−3
Other income0001010111
Finance costs1111111111
Profit before one-off items and tax252672423310−3
One-off items––00000000
Profit before tax252672423310−3
1212266030
Net profit23245171727−3
Net margin2.2%3.5%1.4%3.1%3.0%7.7%5.4%0.8%2.5%−1.1%
Materials, employee costs and other expenses are shown for the years they add up to operating expenses; for the years to Mar 2017 and Mar 2018 they do not, so they are left blank.

Balance sheet

Standalone, ₹ crore, at 31 March.

₹ croreMar 2019Filed 11 JunMar 2020Filed 6 AugMar 2021Filed 6 JulMar 2022Filed 10 JunMar 2023Filed 30 MayMar 2024Filed 4 JulMar 2025Filed 13 JunMar 2026Filed 30 May
2024304763657268
Share capital33333333
Reserves1721274460626965
69981981011
1934273753565056
10000000
Total assets40585785116122121124
79101118191821
3350477499103103104
Net debt486−107−194
Borrowings are counted again inside the liabilities due within a year and after a year. No balance sheet is on record for the years to Mar 2017 and Mar 2018, so its lines and the ratios worked from it are blank there.

Cash flow

Standalone, ₹ crore, years to March.

₹ croreMar 2021Filed 6 JulMar 2022Filed 10 JunMar 2023Filed 30 MayMar 2024Filed 4 JulMar 2025Filed 13 JunMar 2026Filed 30 May
4.817.8−9.49.4−10.18.9
7.119.30.111.8−8.310.7
−1.9−5.4−24.110.1−19.212.3
Receivables−3.9−10.9−7.7−17.612.75.5
Inventories7.4−1.0−20.111.9−17.3−5.6
Payables−5.46.48.515.8−9.14.1
Other working capital0.00.1−4.90.1−5.58.3
Tax paid0.00.0−9.5−2.4−1.5−1.5
Capital spending1.61.31.40.70.43.1
Free cash flow3.216.5−10.88.7−10.55.8
−2.9−1.4−3.0−0.40.0−2.6
−1.9−1.99.6−11.20.5−0.5
Dividends paid0.00.00.30.30.30.3
Shares bought back0.00.00.00.00.00.0
Shares issued0.00.00.00.00.00.0
Net change in cash0.014.5−2.8−2.2−9.65.8
Capital spending is part of cash from investing, and dividends paid, shares bought back and shares issued are part of cash from financing. Each is shown as an amount on a line of its own, and the section's other items are in its total only. No cash flow statement is on record for the years to Mar 2017, Mar 2018, Mar 2019 and Mar 2020.

Per share

Standalone, ₹ per share, years to March.Samrat Pharmachem dividend history

₹ per shareMar 2017Mar 2018Mar 2019Filed 11 JunMar 2020Filed 6 AugMar 2021Filed 6 JulMar 2022Filed 10 JunMar 2023Filed 30 MayMar 2024Filed 4 JulMar 2025Filed 13 JunMar 2026Filed 30 May
Earnings per share₹5.07₹10.41₹4.97₹13.71₹17.26₹55.62₹53.83₹7.00₹23.02−₹10.72
Diluted earnings per share₹5.07₹10.41₹4.97₹13.71₹17.26₹55.62₹53.83₹7.00₹23.02−₹10.72
Dividend per share–––––₹1.00₹1.00₹1.00₹1.00–
Book value per share––₹64.95₹78.66₹95.92₹151.54₹204.37₹210.37₹232.39₹220.67
Dividend payout–––––1.8%1.9%14.3%4.3%–
Shareholder yield––––0.0%0.0%0.3%0.3%0.3%0.5%
Market cap at the year end (₹ crore)24392319421501151039760

Ratios

Standalone, years to March.Samrat Pharmachem PE ratio and valuation

RatioMar 2017Mar 2018Mar 2019Filed 11 JunMar 2020Filed 6 AugMar 2021Filed 6 JulMar 2022Filed 10 JunMar 2023Filed 30 MayMar 2024Filed 4 JulMar 2025Filed 13 JunMar 2026Filed 30 May
Revenue growth–30.0%20.1%23.7%30.2%23.9%40.0%−9.4%1.5%1.4%
Operating profit growth–56.7%−46.6%108.7%30.8%180.8%−1.7%−89.7%314.7%–
Net profit growth–105.4%−52.3%175.9%25.9%222.2%−3.2%−87.0%228.9%–
Earnings per share growth–105.3%−52.3%175.9%25.9%222.2%−3.2%−87.0%228.9%–
––7.7%19.1%19.8%45.0%30.2%3.4%10.4%−4.7%
–––11.4 pts0.7 pts25.2 pts−14.7 pts−26.9 pts7.0 pts−15.1 pts
From the net margin–––9.4 pts−0.6 pts31.7 pts−13.9 pts−25.9 pts7.6 pts−15.2 pts
From asset turnover–––0.2 pts2.0 pts0.5 pts−0.3 pts−1.0 pts−0.1 pts0.0 pts
From borrowing–––1.9 pts−0.7 pts−7.0 pts−0.5 pts0.1 pts−0.5 pts0.1 pts
Return on capital employed––10.6%18.6%21.3%43.7%28.5%2.5%11.7%−3.6%
Cash conversion––––90.6%103.5%−56.7%435.2%−141.9%–
Interest cover4.66.42.66.36.435.218.92.714.2–
Debt to equity––0.300.370.300.160.300.130.140.16
Receivable days––6974677260907264
Inventory days––2855252443285256
Payable days––456739450645355
Cash conversion cycle, days––52615351103537166
Working capital days––5663544462588166
Asset turnover––2.762.793.093.123.092.372.352.36
Assets per rupee of net worth––2.002.222.151.861.831.861.781.76
Sales per rupee of plant––16.2619.1419.0622.2329.0526.2827.3224.76
Capital spending to depreciation––––3.342.152.111.030.634.28
Plant being built, % of plant in use––0.0%15.0%0.0%0.0%–––9.6%
Interest cover is left blank for the year to Mar 2026: operating profit after depreciation is a loss, and a loss covers no interest bill. No balance sheet is on record for the years to Mar 2017 and Mar 2018, so its lines and the ratios worked from it are blank there.

Growth and returns over 3, 5 and 10 years

Standalone: the listed company alone, without its subsidiaries. Each window ends with the year to Mar 2026.

Return on assets, latest year
−2.7%
Measure10 years5 years3 years
Revenue growth, yearly rate–10.1%−2.3%
Return on equity, average–16.8%3.0%
Return on capital employed, average–16.6%3.5%
Operating margin, average4.7%4.5%1.2%
Net margin, average2.8%3.0%0.7%
Asset turnover, average–2.662.36
Cash conversion cycle, days, average–6963
Interest cover, average10.817.78.4
Debt to equity, average–0.180.14

Where the cash came from and went

Standalone: the listed company alone, without its subsidiaries. ₹ crore, added up over each window, which ends with the year to Mar 2026.

₹ crore5 years3 yearsLatest year
Cash from operations16.58.28.9
Cash from investing−7.4−3.0−2.6
Cash from financing−3.5−11.2−0.5
Capital spending6.84.23.1
Dividends paid1.20.90.3
Shares bought back0.00.00.0
Shares issued for cash0.00.00.0
Borrowings raised––0.8
Borrowings repaid1.30.00.0

Accounting checks

Standalone, years to March. Published tests of whether reported profit is backed by cash and the balance sheet.

CheckMar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Piotroski score, out of 9Published threshold 3 points out of 9––––482454
Altman Z-scorePublished threshold 1.81––4.703.905.597.195.854.665.134.11
Beneish M-scorePublished threshold −1.78––––−2.37−2.500.35−1.47−2.27−1.95
Profit not backed by cash, % of assetsPublished threshold 10 per cent of average total assets––––5.911.0928.96−5.7514.15−7.82
Cash from operations to profit, 3 yearsPublished threshold 0.7 times––––––0.340.49−0.391.38
Receivables growth less revenue growthOur threshold 0 percentage points–––8.46−11.578.12−22.4644.57−19.91−11.06
Inventory growth less cost-of-goods growthOur threshold 0 percentage points–––114.27−70.01−6.71115.66−33.7285.138.67
Other current assets growth less revenue growthOur threshold 5 per cent of revenue–––0.29−0.860.080.77−0.021.90−1.91
Assets under construction, years of additionsOur threshold 2 years of additions–––1.400.000.00–––0.57
Effective tax ratePublished threshold 17.16 per cent37.2234.6328.8326.7627.3827.1926.1914.1928.06–
Tax charged less tax paid, % of profitOur threshold 10 percentage points–––––27.19−15.98−81.4713.37–
A threshold marked as ours has no published figure; it is the line we read the check against.

Credit ratings

An agency's view of the chance the company repays a borrowing on time, from AAA, the highest, down to D, in default.

DateAgencyBorrowing ratedRatingOutlookAmount, ₹ Cr
13 Jul 2026CRISIL Ratings Limited (opens in a new tab)Bank FacilitiesLong-term scaleWithdrawnRating Withdrawn28
13 Jul 2026CRISIL Ratings Limited (opens in a new tab)Bank FacilitiesShort-term scaleWithdrawnRating Withdrawn2
The latest rating on each borrowing. The agency's name opens its reasoning for the rating.